Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Ocular Therapeutix closes $14 million Series D financing round

Ocular Therapeutix, Inc. announced today that it has closed a $14 million Series D round of financing. The round was led by Ascension Health Ventures of St. Louis, Missouri, with continued participation by existing investors including Polaris Ventures, SV Life Sciences and Versant Ventures.

3 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Aphios® Corporation today announced that it has entered into a subcontract with SAIC-Frederick, a subsidiary of Science Applications International Corporation, to develop phospholipid nanoencapsulated camptothecin, Camposomes™, for the treatment of pancreatic and other cancers, supporting the NCI Alliance for Nanotechnology.

2 Feb 2011

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

Genzyme Corporation today announced that it has completed the sale of its diagnostic products business to Sekisui Chemical Co., Ltd. for $265 million in cash.

1 Feb 2011

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

Researchers at Memorial Sloan-Kettering Cancer Center's Nanotechnology Center, along with collaborators at Cornell University and Hybrid Silica Technologies, have received approval for their first Investigational New Drug Application from the US Food and Drug Administration for an ultrasmall silica inorganic nanoparticle platform for targeted molecular imaging of cancer, which may be useful for cancer treatment in the future.

31 Jan 2011

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Allergan, and MAP Pharmaceuticals, today announced a collaboration within the United States for LEVADEX, a self-administered, orally inhaled therapy that has completed Phase III clinical development for the treatment of acute migraine in adults.

31 Jan 2011

Warwick research opens new strategy in vehicle design for drug release

The ability of some forms of plankton and bacteria to build an extra natural layer of nanoparticle-like armour has inspired chemists at the University of Warwick to devise a startlingly simple way to give drug bearing polymer vesicles (microscopic polymer based sacs of liquid) their own armoured protection.

31 Jan 2011

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

Apricus Biosciences, today announced that its research and development team at its NexMed, USA, Inc. subsidiary is presenting data demonstrating the use of the Company's proprietary NexACT technology to improve less permeable or less soluable drugs, at the Controlled Release Society Product Development Forum for Poorly Soluble Drugs, being held January 27 to 29, 2011, in Miami, Florida.

29 Jan 2011

FDA approves GRALISE Tablets for treatment of PHN

Depomed, Inc. today announced that US FDA has approved GRALISE (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia, which is pain following healing of the rash associated with shingles.

29 Jan 2011

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Lipocine Inc. announced today that in addition to its issued patents involving oral testosterone, it has recently filed two new patent applications in support of its oral testosterone product for hypogonadism, also known as low testosterone (low T). These applications cover Lipocine's novel oral testosterone product (LPCN 1021) being developed to overcome the issues with currently marketed topical, parenteral, and transdermal testosterone products.

28 Jan 2011

Soligenix and CU enter definitive license agreement for novel vaccine thermostabilization technology

Soligenix, Inc., a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures.

28 Jan 2011

Healthcare at Home acquires Sciensus

Healthcare at Home Ltd, Europe's leading international provider of home-based healthcare and specialty pharmacy services, is today pleased to announce that it has acquired Sciensus Ltd, a provider of health informatics for clients across the NHS and the pharmaceutical industry.

27 Jan 2011

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

A Taiwanese research team, led by Prof. Ming-Shing Young of Department of Electrical Engineering at National Cheng Kung University (NCKU), has successfully developed a large-scale proactive cancer treatment system first-generation prototype which includes Frequency-Adjustable High Frequency Induction Heating Machine (HFIHM) and 3D Magnetically Guiding Endoscope System (3DMGES).

25 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Diamyd Medical's President and CEO Elisabeth Lindner states in the CEO comments in today's quarterly report that the Company expects to begin reporting the results from the European Phase III trial in type 1 diabetes as planned in late spring 2011.

25 Jan 2011

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

Alexza Pharmaceuticals, Inc. announced today that the British Journal of Psychiatry, a publication of the Royal College of Psychiatrists, has published the results of the pivotal Phase 3 study evaluating AZ-004 (inhaled or Staccato® loxapine) for the rapid treatment of agitation in patients with schizophrenia, in its January 2011 edition (198:51-58).

24 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Intellipharmaceutics International Inc. today announced that it has received purchase agreement commitments from institutional investors to provide the Company with approximately US$12,000,000 in gross proceeds through the sale of its common stock and warrants.

21 Jan 2011

Alliqua completes transdermal pain patch initial study for treatment of PHN

Alliqua, an advanced biomedical products company focused on the development and manufacturing of proprietary drug delivery and liver health technologies, announced today the successful completion of its initial study for the transdermal pain patch project.

20 Jan 2011

FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to RiVax™ for the prevention of ricin intoxication. RiVax™ is a proprietary vaccine that contains a recombinant subunit of the A chain of ricin toxin which induces ricin neutralizing antibodies in humans and animals.

20 Jan 2011

Drug Delivery News and Research

Further Reading

Ocular Therapeutix closes $14 million Series D financing round

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Aphios enters subcontract with SAIC-Frederick to develop phospholipid nanoencapsulated camptothecin

Genzyme's diagnostic products sold to Sekisui Chemical for $265 million

FDA approves ultrasmall silica inorganic nanoparticle INDA for targeted molecular imaging of cancer

MAP Pharmaceuticals, Allergan collaborate for LEVADEX to treat acute migraine in adults

Warwick research opens new strategy in vehicle design for drug release

NexMed presents data on NexACT technology use to improve less permeable, soluable oral drugs

FDA approves GRALISE Tablets for treatment of PHN

Lipocine files new patent applications in support of oral testosterone product for hypogonadism

Soligenix and CU enter definitive license agreement for novel vaccine thermostabilization technology

Healthcare at Home acquires Sciensus

Taiwanese research team develops large-scale proactive cancer treatment system first-generation prototype

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd Medical to report European Phase III trial results for type 1 diabetes

Alexza's AZ-004 Phase 3 study in agitated patients with schizophrenia published in British Journal of Psychiatry

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

Intellipharmaceutics receives purchase agreement commitments for $12,000,000

Alliqua completes transdermal pain patch initial study for treatment of PHN

FDA grants Soligenix Orphan Drug Designation to RiVax for prevention of ricin intoxication

Event guide: World ADC Asia eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo